What This Document Is
This document presents a case analysis centered on Mylan Pharmaceutical’s significant price increases for the EpiPen, a life-saving device used to treat severe allergic reactions. It examines the business and ethical challenges faced by Mylan’s CEO, Heather Bresch, in the wake of public and congressional scrutiny. The case explores the complexities of pharmaceutical pricing, the role of insurance and the supply chain, and potential antitrust concerns.
Why This Document Matters
This case study is valuable for students and professionals in business, particularly those focused on strategy, marketing, ethics, and healthcare management. It’s commonly used in Foundations of Business courses to illustrate real-world applications of business principles and the impact of corporate decisions on stakeholders. Understanding this case provides insight into crisis management, public relations, and the broader challenges within the pharmaceutical industry. It’s particularly relevant when considering corporate social responsibility and the balance between profit and public health.
Common Limitations or Challenges
This case analysis focuses specifically on the EpiPen situation at Mylan between 2014-2016. It does not provide a comprehensive overview of the entire pharmaceutical industry or a detailed legal analysis of antitrust law. While it identifies contributing factors to the price increases, it doesn’t offer definitive solutions to the systemic issues within the drug pricing system.
What This Document Provides
The full document includes: a detailed overview of Mylan’s business and financial performance; an examination of the factors contributing to the EpiPen price increases, including perspectives from Heather Bresch; analysis of the public and political backlash; discussion of potential legal challenges related to antitrust violations; and consideration of the ethical implications of Mylan’s actions.
This preview *does not* include the full financial statements, detailed legal arguments, or suggested discussion questions for classroom use. It also does not offer a conclusive resolution to the case or a comprehensive industry analysis.
